Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mega Genomics Limited
美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6667)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON THURSDAY, 21 MAY 2026

Reference is made to the circular of Mega Genomics Limited (the "**Company**") dated 29 April 2026 (the "**Circular**"). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the Annual General Meeting held on Thursday, 21 May 2026, all the resolutions as set out in the notice of the Annual General Meeting dated 29 April 2026 were passed by the shareholders of the Company by way of poll.

The poll results taken at the Annual General Meeting are as follows:

Ordinary Resolutions		**Number of Votes (Approximate %)**	
		For	**Against**
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2025.	89,280,530 (100.00%)	0 (0.00%)
2(a).	To re-elect Dr. Yu Rong as an executive director of the Company.	89,280,530 (100.00%)	0 (0.00%)

* *For identification purposes only*

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
2(b).	To re-elect Ms. Lin Lin as an executive director of the Company.	89,280,530 (100.00%)	0 (0.00%)
2(c).	To re-elect Ms. Guo Meiling as a non-executive director of the Company.	89,280,530 (100.00%)	0 (0.00%)
2(d).	To re-elect Dr. Zhang Ying as an independent non-executive director of the Company.	89,280,530 (100.00%)	0 (0.00%)
3.	To authorize the board of directors (the "**Board**") to fix the remuneration of the directors of the Company.	89,280,530 (100.00%)	0 (0.00%)
4.	To re-appoint Crowe (HK) CPA Limited as auditors of the Company and to authorize the Board to fix their remuneration.	89,280,530 (100.00%)	0 (0.00%)
5.	To declare a final dividend of RMB0.15 per share for the year ended 31 December 2025.	89,280,530 (100.00%)	0 (0.00%)
6.	To grant a general mandate to the directors of the Company to repurchase shares of the Company not exceeding 10% of the total number of issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution.	89,280,530 (100.00%)	0 (0.00%)
7.	To grant a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution.	89,280,530 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
8.	To extend the general mandate granted to the directors of the Company to issue, allot and deal with additional shares (including the sale or transfer of any treasury shares) in the capital of the Company by adding the aggregate number of shares repurchased by the Company.	89,280,530 (100.00%)	0 (0.00%)

As at the date of the Annual General Meeting, the total number of Shares of the Company in issue was 224,300,200 Shares (including 0 treasury Shares). The total number of Shares entitling the holders thereof to attend and vote on all the resolutions at the Annual General Meeting is 224,300,200. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolution at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules and no Shareholder was required under the Listing Rules to abstain from voting at the Annual General Meeting. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the Annual General Meeting. There were no restrictions on any Shareholders to cast votes on any of the resolutions proposed at the Annual General Meeting.

As more than 50% of votes were cast in favour of the above resolutions, they were duly passed by the Shareholders as ordinary resolutions of the Company at the Annual General Meeting.

Ms. Lin Lin and Ms. Jiang Jing, being executive Directors, attended the Annual General Meeting in person. Ms. Guo Meiling, being the non-executive Director, Dr. Zhang Ying, Dr. Xie Dan and Mr. Jia Qingfeng, being the independent non-executive Directors, attended the Annual General Meeting by way of video conference.

The Company's share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the Annual General Meeting.

PAYMENT OF FINAL DIVIDEND

The distribution of the final dividend of RMB0.15 per ordinary share was approved at the Annual General Meeting. As set out in the Circular, the final dividend was declared in RMB, and payable in HKD to the shareholders of the Company. The exchange rate for the final dividend to be paid in HKD will be the average RMB to HKD central parity rate published by the People's Bank of China over the five business days ending on and including the date of the Annual General Meeting, being RMB1 to HK$1.15. Therefore, the final dividend is HK$0.17 per ordinary share. The final dividend is expected to be paid on 9 July 2026 to the shareholders of the Company whose names appear on the register of members of the Company on 29 May 2026.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 21 May 2026

As at the date of this announcement, the executive directors of the Company are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive director of the Company is Ms. Guo Meiling; and the independent non-executive directors of the Company are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.